Hypertriglyceridemia: Molecular and Genetic Landscapes
Abstract
:1. Introduction
2. Methods
3. Triglycerides: From Biochemical Structure to Metabolic Pathways
4. Hypertriglyceridemia: Definition, Classification, and Molecular Background
4.1. The Genetic Landscape of Familial Chylomicronemia Syndrome (FCS)
4.2. Familial Dysbetalipoproteinemia: Genetics and Molecular Mechanisms
4.3. Familial Hypertriglyceridemia and Combined Hyperlipidemia
5. The Role of Hypertriglyceridemia in Cardiovascular Diseases
5.1. Triglycerides and Endothelial Function
5.2. Triglycerides and Cardiac Muscular Cells
6. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- AbouRjaili, G.; Shtaynberg, N.; Wetz, R.; Costantino, T.; Abela, G.S. Current concepts in triglyceride metabolism, pathophysiology, and treatment. Metabolism 2010, 59, 1210–1220. [Google Scholar] [CrossRef]
- Assmann, G.; Schulte, H.; von Eckardstein, A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996, 77, 1179–1184. [Google Scholar] [CrossRef]
- Jeppesen, J.; Hein, H.O.; Suadicani, P.; Gyntelberg, F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97, 1029–1036. [Google Scholar] [CrossRef]
- Criqui, M.H.; Heiss, G.; Cohn, R.; Cowan, L.D.; Suchindran, C.M.; Bangdiwala, S.; Kritchevsky, S.; Jacobs, D.R., Jr.; O’Grady, H.K.; Davis, C.E. Plasma triglyceride level and mortality from coronary heart disease. N. Engl. J. Med. 1993, 328, 1220–1225. [Google Scholar] [CrossRef]
- Manninen, V.; Tenkanen, L.; Koskinen, P.; Huttunen, J.K.; Mänttäri, M.; Heinonen, O.P.; Frick, M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85, 37–45. [Google Scholar] [CrossRef]
- Miller, M.; Seidler, A.; Moalemi, A.; Pearson, T.A. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study. J. Am. Coll. Cardiol. 1998, 31, 1252–1257. [Google Scholar] [CrossRef]
- Castelli, W.P. The triglyceride issue: A view from Framingham. Am. Heart J. 1986, 112, 432–437. [Google Scholar] [CrossRef]
- Sarwar, N.; Danesh, J.; Eiriksdottir, G.; Sigurdsson, G.; Wareham, N.; Bingham, S.; Boekholdt, S.M.; Khaw, K.T.; Gudnason, V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115, 450–458. [Google Scholar] [CrossRef]
- Nordestgaard, B.G.; Benn, M.; Schnohr, P.; Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298, 299–308. [Google Scholar] [CrossRef]
- Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar, N.; Sandhu, M.S.; Ricketts, S.L.; Butterworth, A.S.; Di Angelantonio, E.; Boekholdt, S.M.; Ouwehand, W.; Watkins, H.; Samani, N.J.; et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet 2010, 375, 1634–1639. [Google Scholar]
- Raposeiras-Roubin, S.; Rosselló, X.; Oliva, B.; Fernández-Friera, L.; Mendiguren, J.M.; Andrés, V.; Bueno, H.; Sanz, J.; Martínez de Vega, V.; Abu-Assi, E.; et al. Triglycerides and Residual Atherosclerotic Risk. J. Am. Coll. Cardiol. 2021, 77, 3031–3041. [Google Scholar] [CrossRef]
- Balling, M.; Afzal, S.; Davey Smith, G.; Varbo, A.; Langsted, A.; Kamstrup, P.R.; Nordestgaard, B.G. Elevated LDL Triglycerides and Atherosclerotic Risk. J. Am. Coll. Cardiol. 2023, 81, 136–152. [Google Scholar] [CrossRef]
- Aberra, T.; Peterson, E.D.; Pagidipati, N.J.; Mulder, H.; Wojdyla, D.M.; Philip, S.; Granowitz, C.; Navar, A.M. The association between triglycerides and incident cardiovascular disease: What is “optimal”? J. Clin. Lipidol. 2020, 14, 438–447.e3. [Google Scholar] [CrossRef]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020, 41, 111–188. [Google Scholar] [CrossRef]
- Yen, C.L.; Farese, R.V., Jr. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J. Biol. Chem. 2003, 278, 18532–18537. [Google Scholar] [CrossRef]
- Yen, C.L.; Stone, S.J.; Cases, S.; Zhou, P.; Farese, R.V., Jr. Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase. Proc. Natl. Acad. Sci. USA 2002, 99, 8512–8517. [Google Scholar] [CrossRef]
- Brandt, C.; McFie, P.J.; Stone, S.J. Biochemical characterization of human acyl coenzyme A: 2-monoacylglycerol acyltransferase-3 (MGAT3). Biochem. Biophys. Res. Commun. 2016, 475, 264–270. [Google Scholar] [CrossRef]
- Banh, T.; Nelson, D.W.; Gao, Y.; Huang, T.N.; Yen, M.I.; Yen, C.L. Adult-onset deficiency of acyl CoA:monoacylglycerol acyltransferase 2 protects mice from diet-induced obesity and glucose intolerance. J. Lipid Res. 2015, 56, 379–389. [Google Scholar] [CrossRef]
- Liu, Q.; Siloto, R.M.; Lehner, R.; Stone, S.J.; Weselake, R.J. Acyl-CoA:diacylglycerol acyltransferase: Molecular biology, biochemistry and biotechnology. Prog. Lipid Res. 2012, 51, 350–377. [Google Scholar] [CrossRef]
- Shi, Y.; Cheng, D. Beyond triglyceride synthesis: The dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E10–E18. [Google Scholar] [CrossRef]
- Dash, S.; Xiao, C.; Morgantini, C.; Lewis, G.F. New Insights into the Regulation of Chylomicron Production. Annu. Rev. Nutr. 2015, 35, 265–294. [Google Scholar] [CrossRef]
- Hooper, A.J.; Burnett, J.R.; Watts, G.F. Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circ. Res. 2015, 116, 193–205. [Google Scholar] [CrossRef]
- Kohan, A.B.; Wang, F.; Li, X.; Bradshaw, S.; Yang, Q.; Caldwell, J.L.; Bullock, T.M.; Tso, P. Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G628–G636. [Google Scholar] [CrossRef]
- Wolska, A.; Dunbar, R.L.; Freeman, L.A.; Ueda, M.; Amar, M.J.; Sviridov, D.O.; Remaley, A.T. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis 2017, 267, 49–60. [Google Scholar] [CrossRef]
- Larsson, M.; Vorrsjö, E.; Talmud, P.; Lookene, A.; Olivecrona, G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J. Biol. Chem. 2013, 288, 33997–34008. [Google Scholar] [CrossRef]
- Alves-Bezerra, M.; Cohen, D.E. Triglyceride Metabolism in the Liver. Compr. Physiol. 2017, 8, 1–8. [Google Scholar]
- Tiwari, S.; Siddiqi, S.A. Intracellular trafficking and secretion of VLDL. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1079–1086. [Google Scholar] [CrossRef]
- Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016, 37, 2999–3058. [Google Scholar] [CrossRef]
- Kiss, L.; Fűr, G.; Pisipati, S.; Rajalingamgari, P.; Ewald, N.; Singh, V.; Rakonczay, Z., Jr. Mechanisms linking hypertriglyceridemia to acute pancreatitis. Acta Physiol. 2023, 237, e13916. [Google Scholar] [CrossRef]
- De Villers-Lacasse, A.; Paquette, M.; Baass, A.; Bernard, S. Non-alcoholic fatty liver disease in patients with chylomironemia syndromes. J. Clin. Lipidol. 2023, 17, 475–482. [Google Scholar] [CrossRef]
- Pontremoli, R.; Desideri, G.; Arca, M.; Temporelli, P.L.; Perrone, V.; Dovizio, M.; Borghi, C.; Esposti, L.D.; on the behalf of Local Health Units Group. Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate and risk of end-stage kidney disease in a real-word Italian cohort: Evidence from the TG-RENAL Study. Eur. J. Intern. Med. 2023, 111, 90–96. [Google Scholar] [CrossRef]
- Chait, A.; Subramanian, S. Hypertriglyceridemia: Pathophysiology, Role of Genetics, Consequences, and Treatment. [Updated 2019 Apr 23]. In Endotext [Internet]; Feingold, K.R., Anawalt, B., Boyce, A., Blackman, M.R., Chrousos, G., Corpas, E., Dhatariya, K., Dungan, K., Hofland, H., Kalra, S., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK326743/ (accessed on 6 June 2021).
- Fredrickson, D.S.; Lees, R.S. A system for phenotyping hyperlipoproteinemia. Circulation 1965, 31, 321–327. [Google Scholar] [CrossRef]
- Hegele, R.A.; Ginsberg, H.N.; Chapman, M.J.; Nordestgaard, B.G.; Kuivenhoven, J.A.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Descamps, O.S.; et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014, 2, 655–666. [Google Scholar] [CrossRef]
- Brahm, A.J.; Hegele, R.A. Chylomicronaemia—Current diagnosis and future therapies. Nat. Rev. Endocrinol. 2015, 11, 352–362. [Google Scholar] [CrossRef]
- Borén, J.; Taskinen, M.R.; Björnson, E.; Packard, C.J. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat. Rev. Cardiol. 2022, 19, 577–592. [Google Scholar] [CrossRef]
- Ginsberg, H.N.; Packard, C.J.; Chapman, M.J.; Borén, J.; Aguilar-Salinas, C.A.; Averna, M.; Ference, B.A.; Gaudet, D.; Hegele, R.A.; Kersten, S.; et al. Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur. Heart J. 2021, 42, 4791–4806. [Google Scholar] [CrossRef]
- Gaudet, D.; Karwatowska-Prokopczuk, E.; Baum, S.J.; Hurh, E.; Kingsbury, J.; Bartlett, V.J.; Figueroa, A.L.; Piscitelli, P.; Singleton, W.; Witztum, J.L.; et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur. Heart J. 2020, 41, 3936–3945. [Google Scholar] [CrossRef]
- Gaudet, D.; Clifton, P.; Sullivan, D.; Baker, J.; Schwabe, C.; Thackwray, S.; Scott, R.; Hamilton, J.; Given, B.; Melquist, S.; et al. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. NEJM Evid. 2023, 2, EVIDoa2200325. [Google Scholar] [CrossRef]
- Witztum, J.L.; Gaudet, D.; Freedman, S.D.; Alexander, V.J.; Digenio, A.; Williams, K.R.; Yang, Q.; Hughes, S.G.; Geary, R.S.; Arca, M.; et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N. Engl. J. Med. 2019, 381, 531–542. [Google Scholar] [CrossRef]
- Gouni-Berthold, I.; Alexander, V.J.; Yang, Q.; Hurh, E.; Steinhagen-Thiessen, E.; Moriarty, P.M.; Hughes, S.G.; Gaudet, D.; Hegele, R.A.; O’Dea, L.S.L.; et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021, 9, 264–275. [Google Scholar] [CrossRef]
- Bergmark, B.A.; Marston, N.A.; Prohaska, T.A.; Alexander, V.J.; Zimerman, A.; Moura, F.A.; Murphy, S.A.; Goodrich, E.L.; Zhang, S.; Gaudet, D.; et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N. Engl. J. Med. 2024, 390, 1770–1780. [Google Scholar] [CrossRef]
- Moulin, P.; Dufour, R.; Averna, M.; Arca, M.; Cefalù, A.B.; Noto, D.; D’Erasmo, L.; Di Costanzo, A.; Marçais, C.; Alvarez-Sala Walther, L.A.; et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis 2018, 275, 265–272. [Google Scholar] [CrossRef]
- Goldberg, R.B.; Chait, A. A Comprehensive Update on the Chylomicronemia Syndrome. Front. Endocrinol. 2020, 11, 593931. [Google Scholar] [CrossRef]
- Dron, J.S.; Hegele, R.A. Genetics of Hypertriglyceridemia. Front. Endocrinol. 2020, 11, 455. [Google Scholar] [CrossRef]
- Doolittle, M.H.; Ehrhardt, N.; Péterfy, M. Lipase maturation factor 1: Structure and role in lipase folding and assembly. Curr. Opin. Lipidol. 2010, 21, 198–203. [Google Scholar] [CrossRef]
- Adeyo, O.; Goulbourne, C.N.; Bensadoun, A.; Beigneux, A.P.; Fong, L.G.; Young, S.G. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins. J. Intern. Med. 2012, 272, 528–540. [Google Scholar] [CrossRef]
- Zhang, R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol. 2016, 6, 150272. [Google Scholar] [CrossRef]
- Available online: https://www.ncbi.nlm.nih.gov/gene/27329 (accessed on 28 January 2023).
- Available online: https://www.ncbi.nlm.nih.gov/gene/51129 (accessed on 28 January 2023).
- Haller, J.F.; Mintah, I.J.; Shihanian, L.M.; Stevis, P.; Buckler, D.; Alexa-Braun, C.A.; Kleiner, S.; Banfi, S.; Cohen, J.C.; Hobbs, H.H.; et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J. Lipid Res. 2017, 58, 1166–1173. [Google Scholar] [CrossRef]
- Gallo, A.; Béliard, S.; D’Erasmo, L.; Bruckert, E. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment. Curr. Atheroscler. Rep. 2020, 22, 63. [Google Scholar] [CrossRef]
- Paragh, G.; Németh, Á.; Harangi, M.; Banach, M.; Fülöp, P. Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia. Lipids Health Dis. 2022, 21, 21. [Google Scholar] [CrossRef]
- Koopal, C.; Marais, A.D.; Westerink, J.; Visseren, F.L. Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. J. Clin. Lipidol. 2017, 11, 12–23.e1. [Google Scholar] [CrossRef]
- Smelt, A.H.; de Beer, F. Apolipoprotein E and familial dysbetalipoproteinemia: Clinical, biochemical, and genetic aspects. Semin. Vasc. Med. 2004, 4, 249–257. [Google Scholar] [CrossRef]
- Khalil, Y.A.; Rabès, J.P.; Boileau, C.; Varret, M. APOE gene variants in primary dyslipidemia. Atherosclerosis 2021, 328, 11–22. [Google Scholar] [CrossRef]
- Heidemann, B.E.; Koopal, C.; Baass, A.; Defesche, J.C.; Zuurbier, L.; Mulder, M.T.; Roeters van Lennep, J.E.; Riksen, N.P.; Boot, C.; Marais, A.D.; et al. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene. Clin. Genet. 2022, 102, 253–261. [Google Scholar] [CrossRef]
- Carrasquilla, G.D.; Christiansen, M.R.; Kilpeläinen, T.O. The Genetic Basis of Hypertriglyceridemia. Curr. Atheroscler. Rep. 2021, 23, 39. [Google Scholar] [CrossRef]
- Saeed, A.; Feofanova, E.V.; Yu, B.; Sun, W.; Virani, S.S.; Nambi, V.; Coresh, J.; Guild, C.S.; Boerwinkle, E.; Ballantyne, C.M.; et al. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J. Am. Coll. Cardiol. 2018, 72, 156–169. [Google Scholar] [CrossRef]
- Kajikawa, M.; Maruhashi, T.; Matsumoto, T.; Iwamoto, Y.; Iwamoto, A.; Oda, N.; Kishimoto, S.; Matsui, S.; Aibara, Y.; Hidaka, T.; et al. Relationship between serum triglyceride levels and endothelial function in a large community-based study. Atherosclerosis 2016, 249, 70–75. [Google Scholar] [CrossRef]
- Takaeko, Y.; Maruhashi, T.; Kajikawa, M.; Kishimoto, S.; Yamaji, T.; Harada, T.; Hashimoto, Y.; Han, Y.; Kihara, Y.; Chayama, K.; et al. Lower triglyceride levels are associated with better endothelial function. J. Clin. Lipidol. 2021, 15, 500–511. [Google Scholar] [CrossRef]
- Kajikawa, M.; Higashi, Y. Triglycerides and endothelial function: Molecular biology to clinical perspective. Curr. Opin. Lipidol. 2019, 30, 364–369. [Google Scholar] [CrossRef]
- Giannattasio, C.; Zoppo, A.; Gentile, G.; Failla, M.; Capra, A.; Maggi, F.M.; Catapano, A.; Mancia, G. Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 406–410. [Google Scholar] [CrossRef]
- Norata, G.D.; Grigore, L.; Raselli, S.; Seccomandi, P.M.; Hamsten, A.; Maggi, F.M.; Eriksson, P.; Catapano, A.L. Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. J. Mol. Cell. Cardiol. 2006, 40, 484–494. [Google Scholar] [CrossRef]
- Jönsson-Rylander, A.C.; Nilsson, T.; Fritsche-Danielson, R.; Hammarström, A.; Behrendt, M.; Andersson, J.O.; Lindgren, K.; Andersson, A.K.; Wallbrandt, P.; Rosengren, B.; et al. Role of ADAMTS-1 in atherosclerosis: Remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 180–185. [Google Scholar] [CrossRef]
- Rajamani, A.; Borkowski, K.; Akre, S.; Fernandez, A.; Newman, J.W.; Simon, S.I.; Passerini, A.G. Oxylipins in triglyceride-rich lipoproteins of dyslipidemic subjects promote endothelial inflammation following a high fat meal. Sci. Rep. 2019, 9, 8655. [Google Scholar] [CrossRef]
- Wang, Y.I.; Bettaieb, A.; Sun, C.; DeVerse, J.S.; Radecke, C.E.; Mathew, S.; Edwards, C.M.; Haj, F.G.; Passerini, A.G.; Simon, S.I. Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE 2013, 8, e78322. [Google Scholar] [CrossRef]
- Bermudez, B.; Lopez, S.; Varela, L.M.; Ortega, A.; Pacheco, Y.M.; Moreda, W.; Moreno-Luna, R.; Abia, R.; Muriana, F.J. Triglyceride-rich lipoprotein regulates APOB48 receptor gene expression in human THP-1 monocytes and macrophages. J. Nutr. 2012, 142, 227–232. [Google Scholar] [CrossRef]
- Castoldi, A.; Monteiro, L.B.; van Teijlingen Bakker, N.; Sanin, D.E.; Rana, N.; Corrado, M.; Cameron, A.M.; Hässler, F.; Matsushita, M.; Caputa, G.; et al. Triacylglycerol synthesis enhances macrophage inflammatory function. Nat. Commun. 2020, 11, 4107. [Google Scholar] [CrossRef]
- Takahashi, S. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation. J. Atheroscler. Thromb. 2017, 24, 552–559. [Google Scholar] [CrossRef]
- Eiselein, L.; Wilson, D.W.; Lamé, M.W.; Rutledge, J.C. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H2745–H2753. [Google Scholar] [CrossRef]
- Shin, H.K.; Kim, Y.K.; Kim, K.Y.; Lee, J.H.; Hong, K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol. Circulation 2004, 109, 1022–1028. [Google Scholar] [CrossRef]
- Halle, M.; Eriksson, P.; Tornvall, P. Effects of free fatty acids and a triglyceride-rich fat emulsion on endothelial nitric oxide synthase. Eur. J. Clin. Investig. 2005, 35, 154–155. [Google Scholar] [CrossRef]
- Wang, L.; Sapuri-Butti, A.R.; Aung, H.H.; Parikh, A.N.; Rutledge, J.C. Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H237–H244. [Google Scholar] [CrossRef]
- Rosenblat, M.; Volkova, N.; Paland, N.; Aviram, M. Triglyceride accumulation in macrophages upregulates paraoxonase 2 (PON2) expression via ROS-mediated JNK/c-Jun signaling pathway activation. Biofactors 2012, 38, 458–469. [Google Scholar] [CrossRef]
- Manco, G.; Porzio, E.; Carusone, T.M. Human Paraoxonase-2 (PON2): Protein Functions and Modulation. Antioxidants 2021, 10, 256. [Google Scholar] [CrossRef]
- Yamamoto, T.; Sano, M. Deranged Myocardial Fatty Acid Metabolism in Heart Failure. Int. J. Mol. Sci. 2022, 23, 996. [Google Scholar] [CrossRef]
- Bosma, M.; Dapito, D.H.; Drosatos-Tampakaki, Z.; Huiping-Son, N.; Huang, L.S.; Kersten, S.; Drosatos, K.; Goldberg, I.J. Sequestration of fatty acids in triglycerides prevents endoplasmic reticulum stress in an in vitro model of cardiomyocytelipotoxicity. Biochim. Biophys. Acta 2014, 1841, 1648–1655. [Google Scholar] [CrossRef]
- Zou, L.; Li, X.; Wu, N.; Jia, P.; Liu, C.; Jia, D. Palmitate induces myocardial lipotoxic injury via the endoplasmic reticulum stress—Mediated apoptosis pathway. Mol. Med. Rep. 2017, 16, 6934–6939. [Google Scholar] [CrossRef]
- Schulze, P.C.; Drosatos, K.; Goldberg, I.J. Lipid Use and Misuse by the Heart. Circ. Res. 2016, 118, 1736–1751. [Google Scholar] [CrossRef]
- Hussain, M.M.; Rava, P.; Walsh, M.; Rana, M.; Iqbal, J. Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab. 2012, 9, 14. [Google Scholar] [CrossRef]
- Bartels, E.D.; Nielsen, J.M.; Hellgren, L.I.; Ploug, T.; Nielsen, L.B. Cardiac expression of microsomal triglyceride transfer protein is increased in obesity and serves to attenuate cardiac triglyceride accumulation. PLoS ONE 2009, 4, e5300. [Google Scholar] [CrossRef]
- Bednarski, T.K.; Duda, M.K.; Dobrzyn, P. Alterations of Lipid Metabolism in the Heart in Spontaneously Hypertensive Rats Precedes Left Ventricular Hypertrophy and Cardiac Dysfunction. Cells 2022, 11, 3032. [Google Scholar] [CrossRef]
- Ge, F.; Hu, C.; Hyodo, E.; Arai, K.; Zhou, S.; Lobdell, H., 4th; Walewski, J.L.; Homma, S.; Berk, P.D. Cardiomyocyte triglyceride accumulation and reduced ventricular function in mice with obesity reflect increased long chain Fatty Acid uptake and de novo Fatty Acid synthesis. J. Obes. 2012, 2012, 205648. [Google Scholar] [CrossRef]
- Yagyu, H.; Chen, G.; Yokoyama, M.; Hirata, K.; Augustus, A.; Kako, Y.; Seo, T.; Hu, Y.; Lutz, E.P.; Merkel, M.; et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Investig. 2003, 111, 419–426. [Google Scholar] [CrossRef]
- Kankaanpää, M.; Lehto, H.R.; Pärkkä, J.P.; Komu, M.; Viljanen, A.; Ferrannini, E.; Knuuti, J.; Nuutila, P.; Parkkola, R.; Iozzo, P. Myocardial triglyceride content and epicardial fat mass in human obesity: Relationship to left ventricular function and serum free fatty acid levels. J. Clin. Endocrinol. Metab. 2006, 91, 4689–4695. [Google Scholar] [CrossRef]
- Szczepaniak, L.S.; Dobbins, R.L.; Metzger, G.J.; Sartoni-D’Ambrosia, G.; Arbique, D.; Vongpatanasin, W.; Unger, R.; Victor, R.G. Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 2003, 49, 417–423. [Google Scholar] [CrossRef]
- Khan, R.S.; Kato, T.S.; Chokshi, A.; Chew, M.; Yu, S.; Wu, C.; Singh, P.; Cheema, F.H.; Takayama, H.; Harris, C.; et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: Correction after ventricular assist device implantation. Circ. Heart Fail. 2012, 5, 340–348. [Google Scholar] [CrossRef]
- Prosdocimo, D.A.; Anand, P.; Liao, X.; Zhu, H.; Shelkay, S.; Artero-Calderon, P.; Zhang, L.; Kirsh, J.; Moore, D.; Rosca, M.G.; et al. Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J. Biol. Chem. 2014, 289, 5914–5924. [Google Scholar] [CrossRef]
- Liao, X.; Zhang, R.; Lu, Y.; Prosdocimo, D.A.; Sangwung, P.; Zhang, L.; Zhou, G.; Anand, P.; Lai, L.; Leone, T.C.; et al. Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J. Clin. Investig. 2015, 125, 3461–3476. [Google Scholar] [CrossRef]
- Mardani, I.; Tomas Dalen, K.; Drevinge, C.; Miljanovic, A.; Ståhlman, M.; Klevstig, M.; ScharinTäng, M.; Fogelstrand, P.; Levin, M.; Ekstrand, M.; et al. Plin2-deficiency reduces lipophagy and results in increased lipid accumulation in the heart. Sci. Rep. 2019, 9, 6909. [Google Scholar] [CrossRef]
- Tsai, J.Y.; Kienesberger, P.C.; Pulinilkunnil, T.; Sailors, M.H.; Durgan, D.J.; Villegas-Montoya, C.; Jahoor, A.; Gonzalez, R.; Garvey, M.E.; Boland, B.; et al. Direct regulation of myocardial triglyceride metabolism by the cardiomyocyte circadian clock. J. Biol. Chem. 2010, 285, 2918–2929. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Scicchitano, P.; Amati, F.; Ciccone, M.M.; D’Ascenzi, F.; Imbalzano, E.; Liga, R.; Paolillo, S.; Pastore, M.C.; Rinaldi, A.; Mattioli, A.V.; et al. Hypertriglyceridemia: Molecular and Genetic Landscapes. Int. J. Mol. Sci. 2024, 25, 6364. https://doi.org/10.3390/ijms25126364
Scicchitano P, Amati F, Ciccone MM, D’Ascenzi F, Imbalzano E, Liga R, Paolillo S, Pastore MC, Rinaldi A, Mattioli AV, et al. Hypertriglyceridemia: Molecular and Genetic Landscapes. International Journal of Molecular Sciences. 2024; 25(12):6364. https://doi.org/10.3390/ijms25126364
Chicago/Turabian StyleScicchitano, Pietro, Francesca Amati, Marco Matteo Ciccone, Flavio D’Ascenzi, Egidio Imbalzano, Riccardo Liga, Stefania Paolillo, Maria Concetta Pastore, Andrea Rinaldi, Anna Vittoria Mattioli, and et al. 2024. "Hypertriglyceridemia: Molecular and Genetic Landscapes" International Journal of Molecular Sciences 25, no. 12: 6364. https://doi.org/10.3390/ijms25126364